Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …

Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

HCC is one of the most common cancers worldwide, and the third leading cause of cancer‐
related death globally. HCC comprises nearly 90% of all cases of primary liver cancer …

The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

Background & Aims Immunotherapy with atezolizumab plus bevacizumab represents the
new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC) …

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, typically
develops on the background of chronic liver disease and is an aggressive disease with …